Orphan Drugs Korean Pharmas’ Ticket To Global Success?
This article was originally published in PharmAsia News
Amid limited resources and marketing capabilities, South Korean pharmas are increasingly opting for improved and orphan drugs as their ticket to major global markets. Several companies shared their varying strategies for international success during a recent symposium in Seoul.
You may also be interested in...
ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.